MAIA Biotechnology, Inc. filings document the regulatory record for a clinical-stage oncology company developing ateganosine for non-small cell lung cancer. Form 8-K reports cover THIO-101 clinical updates, oncology conference materials, shareholder communications on the development pipeline, FDA Fast Track disclosure, and forward-looking risk language tied to investigational drug development.
The company’s filings also document capital structure and governance matters, including an underwritten common stock offering conducted under an effective Form S-3 shelf registration, the related underwriting agreement and use-of-proceeds disclosure, executive compensation actions, and annual meeting proxy matters such as director elections and auditor ratification.
MAIA Biotechnology, Inc. registered 751,879 shares of common stock for resale by PoC Capital LLC. MAIA will not receive proceeds from PoC’s sales. Separately, PoC agreed to provide $1,000,000 following the prospectus date, to be applied to company expenses for studies evaluating THIO in patients with cancer.
The shares were received under a Clinical Trial Funding Agreement dated August 29, 2026. PoC may sell all, some or none in public or private transactions at prevailing market prices, prices related to prevailing market prices, or privately negotiated prices. MAIA also states that substantial doubt exists regarding its ability to continue as a going concern and that it will need substantial additional funding.
MAIA Biotechnology, Inc. posted a management presentation and a summary of its operations and performance on its website on October 6, 2026. Management intends to use both materials from time to time in presentations on or after that date. Each speaks as of October 6, 2026, contains forward-looking statements, and is furnished rather than deemed filed for purposes of Section 18 of the Exchange Act; MAIA disclaims an obligation to update either material.
MAIA Biotechnology, Inc. director Theagene Jean-Manasse received a grant of 32,012 stock options on September 30, 2026, under the company’s 2021 Equity Incentive Plan. The options vested 100% on the grant date and became exercisable that day at $1.18 per share. They expire September 30, 2036. His reported post-transaction position is 32,012 stock options.
MAIA Biotechnology, Inc. director Stan Smith reported an award on September 30, 2026, of 38,871 stock options, beneficially owned through The Stan V. Smith Trust Dated 1993. The options cover 38,871 shares of common stock and carry a $1.18 per-share exercise price.
MAIA Biotechnology, Inc. director Cristian Luput received 33,536 stock options under the company’s 2021 Equity Incentive Plan on September 30, 2026, with an exercise price of $1.18 per share. The options represent the right to buy common stock, and the reported position after the grant is 33,536 options.
MAIA Biotechnology director Louie Ngar Yee received 39,634 stock options on September 30, 2026. The options vested 100% on the grant date and were exercisable beginning that day, at an exercise price of $1.18 per share. They expire September 30, 2036, under the company’s 2021 Equity Incentive Plan.
MAIA Biotechnology, Inc. director Ramiro Guerrero received a grant of 32,012 stock options on September 30, 2026, under the company's 2021 Equity Incentive Plan. The options cover the right to buy 32,012 shares of common stock at an exercise price of $1.18 per share; his reported resulting position was 32,012 options.
MAIA Biotechnology, Inc. registered 751,879 shares of common stock for resale by PoC Capital, LLC, which received them under a Clinical Trial Funding Agreement. PoC Capital may sell at prevailing market prices, prices related to prevailing market prices or privately negotiated prices; MAIA will receive no proceeds from these resales.
Separately, PoC Capital agreed to provide $1,000,000 in funding following the prospectus date, to be applied to MAIA's expenses for studies evaluating THIO's safety, tolerability, efficacy and pharmacodynamics in cancer patients.
MAIA describes itself as a clinical-stage company developing investigational ateganosine (THIO). Its Phase 3 THIO-104 trial, initiated in 2025, is designed to compare ateganosine sequenced with a checkpoint inhibitor against chemotherapy in a 1:1 randomization of up to 300 third-line NSCLC patients resistant to checkpoint inhibitors and chemotherapy. MAIA also states there is substantial doubt regarding its ability to continue as a going concern and that it needs substantial additional funding, which may not be available on acceptable terms or at all.
MAIA Biotechnology, Inc. reported a grant of 32,774 stock options to director Steven M. Chaouki on September 30, 2026. The options represent the right to buy common stock at an exercise price of $1.18 per share. They vest 100% on the grant date and are exercisable beginning that date, with an expiration date of September 30, 2036.